MHRAsafety guidance83% confidence
Clinical trials for medicines: ending a clinical trial
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (prostate cancer) as Bayer.
Regulatory Analysis
Guidance on the process for ending a clinical trial.
Supporting Context
- Therapeutic area
- Oncology · Prostate Cancer
- Sub-indication
- Prostate Cancer
Related signal: Bayer's Study on ARPI Use in mHSPC Patients in Australia Aims to Inform Clinical Practice